Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koen Deforche

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Biorxiv : the Preprint Server for Biology|June 9, 2020
Genome Detective Coronavirus Typing Tool for rapid identification and characterization of novel coronavirus genomesSara Cleemput, Wim Dumon, Vagner Fonseca, et al.
Antiviral Therapy|September 13, 2006
Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AGAna B Abecasis, Koen Deforche, Lee T Bacheler, et al.
Journal of Virological Methods|November 8, 2005
A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypesKristel Van Laethem, Yoeri Schrooten, Sarah Dedecker, et al.
Virology Journal|January 25, 2008
HIV-1 gp120 N-linked glycosylation differs between plasma and leukocyte compartmentsYung Shwen Ho, Ana B Abecasis, Kristof Theys, et al.
Retrovirology|February 5, 2008
The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in PortugalJurgen Vercauteren, Koen Deforche, Kristof Theys, et al.
AIDS (London, England)|October 18, 2005
Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or GAna Barroso Abecasis, Koen Deforche, Joke Snoeck, et al.
Nucleic Acids Research|June 2, 2009
A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequencesLuiz Carlos Junior Alcantara, Sharon Cassol, Pieter Libin, et al.
AIDS (London, England)|October 4, 2008
Bayesian network analyses of resistance pathways against efavirenz and nevirapineKoen Deforche, Ricardo J Camacho, Zehave Grossman, et al.
Plos Genetics|March 30, 2012
APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenonAndrew E Armitage, Koen Deforche, Chih-Hao Chang, et al.
Antiviral Therapy|June 25, 2008
Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological responseKoen Deforche, Alessandro Cozzi-Lepri, Kristof Theys, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Biorxiv : the Preprint Server for Biology|June 9, 2020
Genome Detective Coronavirus Typing Tool for rapid identification and characterization of novel coronavirus genomesSara Cleemput, Wim Dumon, Vagner Fonseca, et al.
Antiviral Therapy|September 13, 2006
Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AGAna B Abecasis, Koen Deforche, Lee T Bacheler, et al.
Journal of Virological Methods|November 8, 2005
A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypesKristel Van Laethem, Yoeri Schrooten, Sarah Dedecker, et al.
Virology Journal|January 25, 2008
HIV-1 gp120 N-linked glycosylation differs between plasma and leukocyte compartmentsYung Shwen Ho, Ana B Abecasis, Kristof Theys, et al.
Retrovirology|February 5, 2008
The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in PortugalJurgen Vercauteren, Koen Deforche, Kristof Theys, et al.
AIDS (London, England)|October 18, 2005
Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or GAna Barroso Abecasis, Koen Deforche, Joke Snoeck, et al.
Nucleic Acids Research|June 2, 2009
A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequencesLuiz Carlos Junior Alcantara, Sharon Cassol, Pieter Libin, et al.
AIDS (London, England)|October 4, 2008
Bayesian network analyses of resistance pathways against efavirenz and nevirapineKoen Deforche, Ricardo J Camacho, Zehave Grossman, et al.
Plos Genetics|March 30, 2012
APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenonAndrew E Armitage, Koen Deforche, Chih-Hao Chang, et al.
Antiviral Therapy|June 25, 2008
Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological responseKoen Deforche, Alessandro Cozzi-Lepri, Kristof Theys, et al.
Pageof 4